Chemical Structure (Keppraxr 01)
Keppra Tablet, Film Coated, Extended Release
Product Images NDC 50474-599
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Keppra (NDC 50474-599). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Keppraxr 02)
This appears to be a table or chart showing percentages of patients receiving different doses of a medication (Keppra) and a placebo. The percentages are broken down into various categories, but without additional context it is unclear what those categories represent.*
Figure 2 (Keppraxr 03)
The text seems to be an excerpt from a clinical study report, but it lacks context and information to provide a meaningful description. It mentions some percentages related to patients and treatment with a medication called KEPPRA, as well as a placebo group. However, without knowing the purpose of the study, the criteria for patient selection, the outcomes measured, and other relevant details, it is not possible to provide a useful description of the text.*
Figure 3 (Keppraxr 04)
This is a table containing the percentage of patients and the number of patients (N) in a study comparing placebo and immediate-release Keppra at a dosage of 3000 mg/day. However, without additional context or information, it is difficult to determine what is being studied or what the percentages represent.*
Figure 4 (Keppraxr 05)
Principal Display Panel (500 mg Tablet Bottle Label)
Keppra XR is a trademark of UCBS.A. or its affiliates. The drug is manufactured for UCB, Inc. in Smyrna, GA, with PT# 4001562 and NDC 50474-598-66, 60 tablets for once daily dosing. The tablets are 500mg and are extended-release. Each patient must be given the accompanying medication guide. Dispense in a tight, light-resistant container with a child-resistant closure, and see the package insert for complete dosage recommendations. Store at 25°C (77°F), but excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].*
Principal Display Panel (750 mg Tablet Bottle Label)
KEPPRA XR is a medication used for seizures, it is available in the form of extended-release tablets in doses of 750 mg. The medication comes in a bottle containing 60 tablets, NDC code 50474-599-66. The recommended dosage for KEPPRA varies and should be consulted in the package insert for complete dosage recommendations. It should be dispensed in a tight, light-resistant container with a child-resistant closure. KEPPRA XR must be prescribed by a healthcare professional and should not be taken without their advice.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
